Chris O’Brien MD PhD FCCP
Chief Medical Officer Kinaset Therapeutics Inc
Seminars
Tuesday 15th September 2026
Unlocking Broad COPD Control with Inhaled JAK Inhibition, Utilizing Targeted Delivery for Safer, More Effective Treatment
11:30 am
- Discover how inhaled pan-JAK inhibition could enable treatment across both eosinophilic and non-eosinophilic COPD phenotypes, expanding reach beyond current biologic limitations
- Explore the benefits of dry powder inhalation delivering therapy to the lungs, enhancing local efficacy while minimizing systemic exposure and improving safety profiles
- Understand how targeted pulmonary delivery of small molecules could provide a convenient, scalable alternative to biologics, supporting better patient adherence and clinical outcomes
